NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $59.56 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$59.58 +0.02 (+0.03%) As of 06/12/2026 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CG Oncology Stock (NASDAQ:CGON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CG Oncology alerts:Sign Up Key Stats Today's Range$57.69▼$60.7150-Day Range$53.72▼$74.0052-Week Range$23.65▼$75.50Volume933,767 shsAverage Volume900,542 shsMarket Capitalization$5.25 billionP/E RatioN/ADividend YieldN/APrice Target$81.73Consensus RatingModerate Buy Company Overview CG Oncology, Inc. (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity. Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates. The company’s discovery engine integrates high-throughput screening, structure-based design and biomarker development, enabling rapid iteration and selection of molecules with favorable pharmacological profiles. Since its founding, CG Oncology has built a management team with extensive experience in oncology drug development, regulatory strategy and commercial planning. The organization continues to expand its pipeline by pursuing additional immuno-oncology targets and exploring strategic collaborations to accelerate the translation of its antibody assets from preclinical research into the clinic. Through these efforts, CG Oncology aims to create differentiated therapies that address unmet needs in the treatment of solid tumor malignancies. AI Generated. May Contain Errors. Read More CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreCGON MarketRank™: CG Oncology scored higher than 56% of companies evaluated by MarketBeat, and ranked 467th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCG Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCG Oncology has a consensus price target of $81.73, representing about 37.2% upside from its current price of $59.56.Amount of Analyst CoverageCG Oncology has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CG Oncology are expected to grow in the coming year, from ($2.89) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CG Oncology is -25.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CG Oncology is -25.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCG Oncology has a P/B Ratio of 6.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CG Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.68% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 10.15, which indicates bearish sentiment.Change versus previous monthShort interest in CG Oncology has recently increased by 6.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.75 News SentimentCG Oncology has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for CG Oncology this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,318,170.00 in company stock.Percentage Held by Insiders4.80% of the stock of CG Oncology is held by insiders.Percentage Held by Institutions26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGON Stock News HeadlinesCG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comCG Oncology Shareholders Back Directors and Governance ProposalsJune 8, 2026 | tipranks.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. | Porter & Company (Ad)CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 SharesJune 6, 2026 | insidertrades.comDid CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?May 31, 2026 | finance.yahoo.comCG Oncology to Present at Upcoming Investor Conferences in JuneMay 28, 2026 | globenewswire.comCG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 22, 2026 | businesswire.comWolfe Research initiates coverage of CG Oncology (CGON) with peer perform recommendationMay 19, 2026 | msn.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $41.52 on January 1st, 2026. Since then, CGON shares have increased by 43.4% and is now trading at $59.56. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) issued its quarterly earnings results on Friday, May, 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.13. The company earned $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. When did CG Oncology IPO? CG Oncology (CGON) raised $340 million in an IPO on Thursday, January 25th 2024. The company issued 20,000,000 shares at a price of $16.00-$18.00 per share. Who are CG Oncology's major shareholders? CG Oncology's top institutional investors include Bank of America Corp DE (1.64%), Avidity Partners Management LP (1.46%), EcoR1 Capital LLC (1.25%) and Orbimed Advisors LLC (1.08%). Insiders that own company stock include Hong Fang Song, Brian Guan-Chyun Liu, Decheng Capital Global Life Sc, James Mulay, Corleen M Roche and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings5/08/2026Today6/14/2026Next Earnings (Estimated)8/07/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CGON's financial health is in the Green zone, according to TradeSmith. CGON has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year Founded2010Price Target and Rating Average Price Target for CG Oncology$81.73 High Price Target$100.00 Low Price Target$50.00 Potential Upside/Downside+37.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.99 million Net MarginsN/A Pretax Margin-3,682.61% Return on Equity-23.33% Return on Assets-22.24% Debt Debt-to-Equity RatioN/A Current Ratio31.30 Quick Ratio31.25 Sales & Book Value Annual Sales$4.04 million Price / Sales1,300.30 Cash FlowN/A Price / Cash FlowN/A Book Value$9.33 per share Price / Book6.38Miscellaneous Outstanding Shares88,200,000Free Float83,968,000Market Cap$5.25 billion OptionableOptionable Beta0.31 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CGON) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
